Vertex completes $10.0 billion acquisition of Crinetics Pharmaceuticals
The merger closed September 1, 2026, converting Crinetics shares into $85.00 per share in cash and installing new leadership at the surviving subsidiary.
SEC filing
Latest
3 stories
Tuesday, September 1
Monday, August 3
Crinetics reports Q2 2026 results alongside pending $10 billion Vertex acquisition
Crinetics disclosed the Vertex merger agreement, an FDA rare pediatric disease designation for atumelnant, and PALSONIFY sales growth in its second-quarter update.
SEC filing
Friday, July 10
Crinetics discloses non-compete deals with executives tied to Vertex merger
The agreements, signed July 6, 2026, restrict Crinetics' CEO, CFO, CSO, and chief commercial officer from competing for a year after the deal closes.
SEC filing